What is Daybue (trofinetide) and how are sales typically tracked?
Daybue (trofinetide) is a drug used for Rett syndrome. “Daybue sales” usually refers to commercial revenue reported by the company (and sometimes estimates compiled by analysts), often broken out by geography (U.S. vs. ex-U.S.) and by period (quarterly and full-year).
If you mean “current sales numbers,” those figures can change with each earnings release, because the drug is typically sold through a combination of specialty distribution and payer reimbursement rather than mass retail.
Where can I find the latest Daybue revenue figures?
The most reliable, regularly updated source for “Daybue sales” is the company’s financial reporting (earnings press releases and quarterly reports). News coverage and market-research summaries often quote those numbers.
If you tell me which timeframe you want (for example, “most recent quarter” or “2023 full year”) and whether you want U.S.-only or worldwide, I can help you locate the right reporting period and interpret what the sales line items mean.
How do analysts estimate Daybue sales (and why might numbers differ)?
Analyst/market databases sometimes differ from company-reported revenue because of:
- Timing (billings vs. revenue recognition)
- Sales geography splits
- Whether they include net price adjustments (rebates, chargebacks)
- Inclusion/exclusion of wholesaler channel fill
So two sources can both be “correct” in different ways, depending on methodology.
Does Daybue have major patent/legal issues that affect revenue?
Patent and exclusivity issues can matter for long-term sales expectations. For patent-related detail and tracking, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/
Quick clarification so I can answer with the exact numbers you want
When you say “Daybue sales,” do you want:
1) The latest quarterly revenue,
2) A specific year’s total sales, or
3) A forecast/market estimate?
Reply with the timeframe (e.g., “Q1 2026” or “2025 full year”) and I’ll focus on that.
Sources